Summary:
- This article discusses the relationship between chemotherapy toxicities and low skeletal muscle mass in patients with non-metastatic colorectal cancer (CRC).
- The study found that patients with low skeletal muscle mass were more likely to experience severe chemotherapy-related toxicities, such as neutropenia, diarrhea, and fatigue.
- The findings suggest that assessing skeletal muscle mass before and during chemotherapy treatment may help identify patients at higher risk of experiencing severe side effects, allowing for personalized treatment approaches.